Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Dec 20;9(8):188–199. doi: 10.5306/wjco.v9.i8.188

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.

PMC Copyright notice

Schematic representation of the study of anti-tumor effect of Survivin, luteinizing hormone-releasing hormone fusion protein individually and in combination. The study was conducted on four groups of mice: Untreated or control, Survivin alone, LHRH(6leu)LTB alone and Survivin + LHRH(6leu)LTB. Individual recombinant proteins were purified and used as immunogen along with Mycobacterium indicus pranii as an immunomodulator in murine model. The mice from all the groups were further challenged with tumor cells, 4T1 and tumor development was observed in each group. LHRH fusion protein was not effective in suppressing tumor alone. However, the combination of both Survivin and LHRH(6leu)LTB inhibited tumor growth substantially followed by Survivin alone. LHRH: Luteinizing hormone-releasing hormone.